About
Oxidative Phosphorylation Disruption Therapies for IBD
Areas of Focus
Categories
Small Molecule PharmaceuticalSoutheastern U.S.
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
10
As Collaborator
0
Total Enrollment
410
By Phase
PHASE2: 8PHASE1/PHASE2: 1EARLY_PHASE1: 1
By Status
COMPLETED: 4TERMINATED: 4WITHDRAWN: 2
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT05719311Lead Sponsor
Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
PHASE2Completed
13 participants
Started: Feb 1, 2023 · Completed: Jul 28, 2023
NCT04436458Lead Sponsor
Niclosamide In Moderate COVID-19
PHASE2Withdrawn
Started: Jan 20, 2022 · Completed: Jan 20, 2022
NCT04542434Lead Sponsor
Niclosamide in COVID-19
PHASE2Withdrawn
Started: Jan 20, 2022 · Completed: Jan 20, 2022
NCT04858425Lead Sponsor
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
PHASE2Terminated
166 participants
Started: Apr 30, 2021 · Completed: Sep 10, 2023
NCT04839575Lead Sponsor
Study of Latiglutenase in T1D/CD Patients
PHASE2Terminated
13 participants
Started: Apr 6, 2021 · Completed: Dec 19, 2022
Locations (1)
Headquarters
Boca Raton, FL, United States
Map
Loading map...